• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    CTS Corporation Announces Appointment of Amy M. Dodrill to its Board of Directors

    2/8/24 5:30:00 PM ET
    $CTS
    $PRCT
    Electrical Products
    Technology
    Medical/Dental Instruments
    Health Care
    Get the next $CTS alert in real time by email

    LISLE, Ill., Feb. 08, 2024 (GLOBE NEWSWIRE) -- CTS Corporation (NYSE:CTS), a leading global designer and manufacturer of custom engineered solutions that "Sense, Connect and Move," today announced that Amy M. Dodrill has been appointed to its board of directors, effective February 8, 2024, and will serve as a member of the nominating, governance and sustainability and technology and transactions committees.

    Ms. Dodrill comes to CTS with over 25 years of experience in medical and technology companies and a proven track record of successfully leading and profitably growing global businesses serving key end markets. Ms. Dodrill most recently served as President of Baxter's Global Surgical Solutions and Patient Support Systems segment, a $2 billion business with innovative products focused on advancing connected care and patient outcomes. In that role, Ms. Dodrill successfully integrated two former Hillrom business units into Baxter. Ms. Dodrill is a member of the board of directors of Procept BioRobotics (NASDAQ:PRCT), a commercial stage surgical robotics company, serving on the audit and compensation committees.

    "CTS is pleased to welcome Amy Dodrill to the CTS board.   Her extensive experience in the medical end market and background leading global businesses make her a valuable addition to our already highly experienced and diverse group of directors as CTS continues to focus on growth, end-market diversification, and products that sense, connect and move," said Kieran O'Sullivan, Chairman, President and CEO of CTS.

    About CTS

    CTS (NYSE:CTS) is a leading designer and manufacturer of products that Sense, Connect, and Move. The company manufactures sensors, actuators, and electronic components in North America, Europe, and Asia, and provides engineered products to customers in the aerospace/defense, industrial, medical, and transportation markets. For more information, visit www.ctscorp.com.

    Contact

    Ashish Agrawal

    Vice President and Chief Financial Officer

    CTS Corporation

    4925 Indiana Avenue

    Lisle, IL 60532

    USA

    Telephone: +1 (630) 577-8800

    Email: [email protected]



    Primary Logo

    Get the next $CTS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CTS
    $PRCT

    CompanyDatePrice TargetRatingAnalyst
    PROCEPT BioRobotics Corporation
    $PRCT
    12/2/2024$105.00Overweight
    Morgan Stanley
    PROCEPT BioRobotics Corporation
    $PRCT
    11/14/2024$95.00Hold
    Jefferies
    CTS Corporation
    $CTS
    2/7/2024$46.00Buy → Neutral
    Sidoti
    CTS Corporation
    $CTS
    2/7/2024$38.00 → $46.00Market Perform
    TD Cowen
    PROCEPT BioRobotics Corporation
    $PRCT
    8/11/2023$42.00Overweight
    Piper Sandler
    PROCEPT BioRobotics Corporation
    $PRCT
    5/31/2023Outperform
    William Blair
    CTS Corporation
    $CTS
    11/22/2022$44.00Hold
    Jefferies
    PROCEPT BioRobotics Corporation
    $PRCT
    10/31/2022Neutral
    BTIG Research
    More analyst ratings

    $CTS
    $PRCT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Morgan Stanley initiated coverage on PROCEPT BioRobotics with a new price target

      Morgan Stanley initiated coverage of PROCEPT BioRobotics with a rating of Overweight and set a new price target of $105.00

      12/2/24 7:01:00 AM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • Jefferies initiated coverage on PROCEPT BioRobotics with a new price target

      Jefferies initiated coverage of PROCEPT BioRobotics with a rating of Hold and set a new price target of $95.00

      11/14/24 8:28:45 AM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • CTS Corp downgraded by Sidoti with a new price target

      Sidoti downgraded CTS Corp from Buy to Neutral and set a new price target of $46.00

      2/7/24 8:52:47 AM ET
      $CTS
      Electrical Products
      Technology

    $CTS
    $PRCT
    SEC Filings

    See more
    • SEC Form 144 filed by PROCEPT BioRobotics Corporation

      144 - PROCEPT BioRobotics Corp (0001588978) (Subject)

      6/6/25 4:22:07 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • SEC Form SD filed by CTS Corporation

      SD - CTS CORP (0000026058) (Filer)

      5/30/25 12:19:08 PM ET
      $CTS
      Electrical Products
      Technology
    • CTS Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - CTS CORP (0000026058) (Filer)

      5/12/25 11:47:03 AM ET
      $CTS
      Electrical Products
      Technology

    $CTS
    $PRCT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CTS Corporation Declares a Dividend

      LISLE, Ill., May 12, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of CTS Corporation (NYSE:CTS) has declared a cash dividend of $0.04 per share on outstanding shares of common stock, without par value, to be paid on July 25, 2025, to shareholders of record at the close of business on June 27, 2025. About CTS CTS Corporation (NYSE:CTS) is a leading designer and manufacturer of products that Sense, Connect and Move. CTS manufactures sensors, actuators and electronic components in North America, Europe and Asia, and provides engineered products to customers in the aerospace/defense, industrial, medical and transportation markets. For more information, visit www.ctscorp.com. Contact Ash

      5/12/25 8:33:19 PM ET
      $CTS
      Electrical Products
      Technology
    • CTS Announces First Quarter 2025 Results

      LISLE, Ill., April 30, 2025 (GLOBE NEWSWIRE) -- CTS Corporation (NYSE:CTS), a leading global designer and manufacturer of custom engineered solutions that "Sense, Connect and Move," today announced first quarter 2025 results. "Our global teams continued to execute well in a challenging operating environment. We delivered double digit sales growth in our diversified markets," said Kieran O'Sullivan, CEO of CTS Corporation. "Additionally, we had strong bookings in the quarter in the medical, aerospace and defense, and industrial markets. Diversification remains a strategic priority as we focus on growing our revenues and quality of earnings, both organically and through strategic acquisitio

      4/30/25 8:00:00 AM ET
      $CTS
      Electrical Products
      Technology
    • PROCEPT BioRobotics® to Attend Four Upcoming Investor Conferences in May & June

      SAN JOSE, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today that members of management will present at four upcoming investor conferences in May and June. 2025 Bank of America Health Care Conference Location – Las Vegas, NVFireside Chat – Wednesday, May 14 at 3pm PT / 6pm ET 45th Annual William Blair Growth Stock Conference Location – Chicago, ILPresentation – Wednesday, June 4 at 10am CT / 11am ET 2025 Jefferies Global Healthcare Conference Location – New York City, NYFireside Chat – Thursday, June 5 at 8:45m ET

      4/29/25 4:03:00 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care

    $CTS
    $PRCT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Desai Antal Rohit sold $4,719,492 worth of shares (75,000 units at $62.93) and was granted 1,538 shares, increasing direct ownership by 22% to 8,403 units (SEC Form 4)

      4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

      6/12/25 7:28:32 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • Director Moll Frederic H was granted 1,538 shares, increasing direct ownership by 0.18% to 843,159 units (SEC Form 4)

      4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

      6/12/25 4:27:36 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • Director Sandoval Elisabeth was granted 1,538 shares, increasing direct ownership by 14% to 12,561 units (SEC Form 4)

      4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

      6/12/25 4:26:45 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care

    $CTS
    $PRCT
    Leadership Updates

    Live Leadership Updates

    See more
    • Deborah Kilpatrick Joins Sonder Capital as its Newest Venture Partner

      SAN CARLOS, Calif., Oct. 28, 2024 /PRNewswire/ -- Sonder Capital, a leading healthcare venture firm focused on innovative technologies ushering in a new standard of care in medicine, announced the addition of Deborah Kilpatrick, Ph.D., former CEO of Evidation Health and co-founder of MedtechWomen, as a Venture Partner. Kilpatrick earned her Ph.D. from Georgia Tech in mechanical engineering with a focus in bioengineering and a minor in applied mathematics. Most recently, she was the CEO and Executive Chair of the Board at Evidation Health, a technology company that pioneered th

      10/28/24 7:00:00 AM ET
      $ISRG
      $PRCT
      $SNBR
      $SWAV
      Industrial Specialties
      Health Care
      Medical/Dental Instruments
      Home Furnishings
    • Jupiter Endovascular Exits Stealth With $21M in New Financing to Fund Pivotal Trial for Pulmonary Embolism

      Carl J. St. Bernard Appointed as Chief Executive Officer Jupiter Endovascular, Inc., a medical technology startup developing a new class of endovascular procedures using Endoportal ControlTM to bring the precision and control of direct surgical access to catheter-based interventions, announced today that it has exited stealth mode with a $21 million new round of financing. Sonder Capital was a key participant in the round that included participation from multiple strategic investors. The funding will be used to support the company's upcoming pivotal trial for Pulmonary Embolism and development of additional clinical applications of the Endoportal ControlTM technology. "For decades, the

      8/15/24 10:00:00 AM ET
      $ISRG
      $PRCT
      Industrial Specialties
      Health Care
      Medical/Dental Instruments
    • Sonder Capital Appoints Kate Garrett as Managing Partner to Lead Next Generation of Growth

      Co-founders and industry luminaries Dr. Fred Moll and Jay Watkins will assume the newly created role of Co-chair as firm closes its latest fund, Futures II Sonder Capital, a leading venture capital firm focused on identifying teams and technologies that will transform healthcare, today announced the appointment of firm Co-founder Kate Garrett as Managing Partner. In this pivotal role, Garrett will spearhead Sonder's next phase of growth as the firm closes Sonder Futures II, its second early stage fund. With Garrett becoming Managing Partner, Sonder Co-founders and industry luminaries Fred Moll, M.D. and Jay Watkins will maintain their roles as partners and assume the newly created posit

      4/2/24 8:00:00 AM ET
      $ISRG
      $PRCT
      $SWAV
      Industrial Specialties
      Health Care
      Medical/Dental Instruments

    $CTS
    $PRCT
    Financials

    Live finance-specific insights

    See more
    • CTS Corporation Declares a Dividend

      LISLE, Ill., May 12, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of CTS Corporation (NYSE:CTS) has declared a cash dividend of $0.04 per share on outstanding shares of common stock, without par value, to be paid on July 25, 2025, to shareholders of record at the close of business on June 27, 2025. About CTS CTS Corporation (NYSE:CTS) is a leading designer and manufacturer of products that Sense, Connect and Move. CTS manufactures sensors, actuators and electronic components in North America, Europe and Asia, and provides engineered products to customers in the aerospace/defense, industrial, medical and transportation markets. For more information, visit www.ctscorp.com. Contact Ash

      5/12/25 8:33:19 PM ET
      $CTS
      Electrical Products
      Technology
    • CTS Announces First Quarter 2025 Results

      LISLE, Ill., April 30, 2025 (GLOBE NEWSWIRE) -- CTS Corporation (NYSE:CTS), a leading global designer and manufacturer of custom engineered solutions that "Sense, Connect and Move," today announced first quarter 2025 results. "Our global teams continued to execute well in a challenging operating environment. We delivered double digit sales growth in our diversified markets," said Kieran O'Sullivan, CEO of CTS Corporation. "Additionally, we had strong bookings in the quarter in the medical, aerospace and defense, and industrial markets. Diversification remains a strategic priority as we focus on growing our revenues and quality of earnings, both organically and through strategic acquisitio

      4/30/25 8:00:00 AM ET
      $CTS
      Electrical Products
      Technology
    • PROCEPT BioRobotics Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

      SAN JOSE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended March 31, 2025. Recent Highlights Total revenue of $69.2 million for the first quarter of 2025, an increase of 55% compared to the prior year period in 2024U.S. handpiece and consumables revenue of 38.0 million for the first quarter of 2025, an increase of 61% compared to the prior year period in 2024Sold 43 new robotic sy

      4/24/25 7:00:00 AM ET
      $PRCT
      Medical/Dental Instruments
      Health Care

    $CTS
    $PRCT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by PROCEPT BioRobotics Corporation

      SC 13G/A - PROCEPT BioRobotics Corp (0001588978) (Subject)

      11/14/24 1:28:32 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by CTS Corporation

      SC 13G/A - CTS CORP (0000026058) (Subject)

      11/14/24 1:28:29 PM ET
      $CTS
      Electrical Products
      Technology
    • SEC Form SC 13G filed by CTS Corporation

      SC 13G - CTS CORP (0000026058) (Subject)

      11/14/24 12:28:26 PM ET
      $CTS
      Electrical Products
      Technology